Get started
Author

H. Dobashi

Institution: Kagawa University
OpenAlex ID: A5007687720
Pos0939 Bimekizumab in Patients With Active Non-radiographic Axial Spondyloarthritis: 24-week Efficacy & Safety From Be Mobile 1, a Phase 3, Multicentre, Randomised, Placebo‑controlled Study
2022 · A. Deodhar, D. Van der Heijde, et al. · Annals of the Rheumatic Diseases · 5
PDF
Abs0312 Efficacy of Avacopan as Induction Therapy in Anca-associated Vasculitis: a Japanese Multicenter Cohort Study (j-canvas Study)
2025 · K. Mori, T. Shirai, et al. · Annals of the Rheumatic Diseases · 1
POS0305 THE EFFICACY AND SAFETY OF AVACOPAN IN REMISSION INDUCTION THERAPY FOR MPA/GPA AND THE EFFECTS OF AVACOPAN ON SERUM C5a AND S100A9 LEVELS: A SINGLE-CENTER STUDY IN JAPAN
2024 · Y. Ushio, R. Wakiya, et al. · Annals of the Rheumatic Diseases · 1
Ab1063 Serum S100 in Systemic Lupus Erythematosus Reflects Treatment Response
2024 · R. Wakiya, Y. Ushio, et al. · Annals of the Rheumatic Diseases · 1
Ab1489 Clinical Courses and Pregnancy Outcomes of Twelve Cases Complicated With Behcet's Disease in Our Institution
2023 · H. Shimada, R. Wakiya, et al. · Annals of the Rheumatic Diseases · 1
PDF
Ab0497 Immunological Disease Activity Parameters at Conception Are Risk Factors for Preterm Birth and Low Birth Weight in Patients With Systemic Lupus Erythematosus
2022 · H. Shimada, R. Wakiya, et al. · Annals of the Rheumatic Diseases · 1
PDF
POS0915 MYOSITIS-SPECIFIC AND ASSOCIETED ANTIBODIES, ESPECIALLY ANTI-ARS ANTIBODIES AND ANTI-Ro52 ANTIBODY MAY PREDICT THE CHARACTERISTICS AND FIBROSING PROGRESS OF INTERSTITIAL LUNG DISEASE WITH DERMATOMYOSITIS / POLYMYOSITIS
2022 · S. Nakashima, H. Nakaishi, et al. · Annals of the Rheumatic Diseases · 1
PDF
Abs0589 Avacopan in Combination With Rituximab Achieves a High Remission Rate in Mpa/gpa Despite the Lack of Reduction in Serum Anca Levels
2025 · Y. Ushio, H. Shimada, et al. · Annals of the Rheumatic Diseases
Abs0680 the Risk Factor for Qt Interval Prolongation Caused by Hydroxychloroquine in Sle Patients
2025 · M. Mizusaki, H. Shimada, et al. · Annals of the Rheumatic Diseases
Pos0921 Clinical Characteristics of Japanese Behcet’s Disease Patients With Arthritis
2024 · K. Sugihara, R. Wakiya, et al. · Annals of the Rheumatic Diseases
Ab0836 Significance of Ro52 and Pregnancy Outcomes in Anti-ss-a Antibody Positive Rheumatic Disease Patients
2024 · H. Shimada, R. Mino, et al. · Annals of the Rheumatic Diseases
Ab0941 Fecal Calprotectin in Japanese Patient With Spondyloarthritis
2024 · K. Sugihara, H. Shimada, et al. · Annals of the Rheumatic Diseases
Ab0643 the Analysis of Risk Factors for Preterm Birth and Low Birth Weight in Sle Patients With or Without Attained Lldas at the Conception
2023 · H. Shimada, R. Wakiya, et al. · Annals of the Rheumatic Diseases
PDF
POS1220 HUMORAL IMMUNE RESPONSE AGAINST BNT162b2 mRNA COVID-19 VACCINE IN JAPANESE RHEUMATIC DISEASE PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY: A MONOCENTRIC STUDY
2022 · K. Sugihara, R. Wakiya, et al. · Annals of the Rheumatic Diseases
PDF
AB0689 Clinical courses and pregnancy outcomes of eight cases complicated with Polymyositis/Dermatomyositis (PM/DM) in single center | Annals of the Rheumatic Diseases
2022 · R. Mino, H. Shimada, et al. · Annals of the Rheumatic Diseases
PDF
Ab0313 Clinical Feature of 100 Cases of Methotrexate Associated Lymphoproliferative Disorders With Ra Patient
2022 · T. Kameda, Y. Ushio, et al. · Annals of the Rheumatic Diseases
PDF
Ab0442 Even in Systemic Lupus Erythematosus That Has Achieved Sustained Lldas, Additional Administration of Hydroxychloroquine Should Be Considered.
2022 · R. Wakiya, K. Ueeda, et al. · Annals of the Rheumatic Diseases
PDF
Pos1362 the Efficacy and Cytokine Profiles During Treatment With Apremilast in Patients With Behçet ‘s Disease
2022 · R. Wakiya, Y. Ushio, et al. · Annals of the Rheumatic Diseases
PDF
Ab0438 Efficacy of Belimumab Treatment for Systemic Lupus Erythematosus at Our Hospital
2022 · M. Mizusaki, R. Wakiya, et al. · Annals of the Rheumatic Diseases
PDF
Ab0397 Disease Activity of Rheumatoid Arthritis Were Significantly Decreased by Switching Jak Inhibitor to Another Jak Inhibitor
2022 · T. Miyagi, R. Wakiya, et al. · Annals of the Rheumatic Diseases
PDF
Works count: 20
Citation count: 11
H-index: 1
I10-index:
Year
Topic
Type